Endometrial carcinoma (EnCa) is one of the deadliest gynecological malignancies. The purpose of the current study was to develop an immune-related lncRNA prognostic signature for EnCa. In the current research, a series of systematic bioinformatics analyses were conducted to develop a novel immune-related lncRNA prognostic signature to predict disease-free survival (DFS) and response to immunotherapy and chemotherapy in EnCa. Based on the newly developed signature, immune status and mutational loading between high‑ and low‑risk groups were also compared. A novel 13-lncRNA signature associated with DFS of EnCa patients was ultimately developed using systematic bioinformatics analyses. The prognostic signature allowed us to distinguish samples with different risks with relatively high accuracy. In addition, univariate and multivariate Cox regression analyses confirmed that the signature was an independent factor for predicting DFS in EnCa. Moreover, a predictive nomogram combined with the risk signature and clinical stage was constructed to accurately predict 1-, 2-, 3-, and 5-year DFS of EnCa patients. Additionally, EnCa patients with different levels of risk had markedly different immune statuses and mutational loadings. Our findings indicate that the immune-related 13-lncRNA signature is a promising classifier for prognosis and response to immunotherapy and chemotherapy for EnCa.

中文翻译：

---

开发一种新的免疫相关 lncRNA 标记作为子宫内膜癌的预后分类器

子宫内膜癌（EnCa）是最致命的妇科恶性肿瘤之一。本研究的目的是为 EnCa 开发免疫相关的 lncRNA 预后特征。在目前的研究中，进行了一系列系统的生物信息学分析，以开发一种新的免疫相关 lncRNA 预后特征，以预测 EnCa 中的无病生存期 (DFS) 和对免疫治疗和化疗的反应。基于新开发的特征，还比较了高风险组和低风险组之间的免疫状态和突变负荷。最终使用系统的生物信息学分析开发了与 EnCa 患者 DFS 相关的新型 13-lncRNA 特征。预后特征使我们能够以相对较高的准确度区分具有不同风险的样本。此外，单变量和多变量 Cox 回归分析证实，该特征是预测 EnCa 中 DFS 的独立因素。此外，构建了一个结合风险特征和临床分期的预测列线图，以准确预测 EnCa 患者的 1 年、2 年、3 年和 5 年 DFS。此外，具有不同风险水平的 EnCa 患者具有明显不同的免疫状态和突变负荷。我们的研究结果表明，免疫相关的 13-lncRNA 特征是用于预后和对 EnCa 免疫疗法和化学疗法的反应的有希望的分类器。具有不同风险水平的 EnCa 患者具有明显不同的免疫状态和突变负荷。我们的研究结果表明，免疫相关的 13-lncRNA 特征是用于预后和对 EnCa 免疫疗法和化学疗法的反应的有希望的分类器。具有不同风险水平的 EnCa 患者具有明显不同的免疫状态和突变负荷。我们的研究结果表明，免疫相关的 13-lncRNA 特征是用于预后和对 EnCa 免疫疗法和化学疗法的反应的有希望的分类器。